Ipsen appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital
Paris (France), 16 February 2022 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Catherine Abi-Habib as EVP Strategy, Transformation, and Digital, effective March 1st, 2022. Based in Boulogne-Billancourt, France, she will be reporting directly to David Loew, CEO, Ipsen, and serve on the Executive Leadership Team (ELT). She is replacing Dominique Bery, who after successfully leading the Strategy, Transformation and Digital teams, will move to a new position within Ipsen as head of Nordics & Baltics.
“Along with the ELT, I am very pleased to welcome Catherine to Ipsen. Working across pharma on many important transformation topics, Catherine’s experience in the life science industry reflects the importance of novel customer engagement models across the many stakeholders who shape our healthcare systems around the world. Her passion for harnessing the power of digital and analytics to drive innovation and improve the experience of physicians and patients matches our Group strategy to Focus. Together. For Patients and Society.” said David Loew, CEO, Ipsen.
Catherine brings more than 10 years of experience working with pharmaceutical and biotech companies, medical device manufacturers, health systems, payors, providers, and charitable foundations. She joins Ipsen from McKinsey, where she was a Partner in the Life Sciences Practice based in London, focused on transforming company performance, including reshaping strategy, refining the operating model, defining and implementing commercial approaches, optimizing spend, and identifying opportunities for growth.
Working closely with QuantumBlack, McKinsey’s Advanced Analytics firm, she has partnered with leading biopharma companies on large-scale digital and analytics driven transformations across North America, Europe and Asia, focused on improving physician experience.
“I am inspired by Ipsen’s ambitious innovation agenda and vision to serve physicians and patients in areas of high unmet need. I look forward to working with my new colleagues to drive the transformation to become a leading global mid-size biotech company focused on innovation and Specialty Care.”
Catherine speaks Arabic, English, French, and Italian and holds an MSc. in Economics from the London School of Economics and a BA in Mathematics from Cambridge University, Trinity College.
Attachment
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
Ipsen receives its second Shingo Prize for operational excellence
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis